You need to know this Canadian biotech stock, analyst says

Andre Uddin of Research Capital maintained a “Speculative Buy” rating and C$14.00 price target on Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) following fourth-quarter results and updated clinical data.

In a March 17 note, Uddin said the company continues to show encouraging progress in its lead drug program, with new trial results pointing to meaningful symptom improvement and a clean safety profile.

The latest data showed patients receiving a higher dose experienced an average four-point reduction in symptoms, exceeding the roughly three-point improvement typically considered meaningful.

Uddin said the durability of that improvement is particularly encouraging and could translate into better quality of life over time.

While additional data is still needed, including more detailed tissue-level results, Uddin said early findings support continued development, with similar outcomes possible in the ongoing mid-stage study.

Importantly, no serious safety issues have been reported across the trial to date.

Lower-dose groups also showed sustained benefits over time, with improvement rates holding up through one year. A small adjustment to the drug delivery method in one cohort also appeared to improve results, reinforcing confidence in the treatment approach.

Uddin said the company’s focus remains on clinical progress rather than near-term financial results. Eupraxia reported a Q4 net loss of $16.7-million, wider than expected due to increased research spending, which the analyst said is consistent with advancing its pipeline.

The company ended the year with $80.6-million in cash and no debt, and subsequently raised an additional $63.2-million, bringing its pro-forma cash position to about $127-million. Uddin said this should be sufficient to fund ongoing trials, including a planned late-stage study.

He added that a secondary drug program in osteoarthritis remains a potential upside lever if the company is able to secure a development partner.

Overall, Uddin said Eupraxia continues to stand out for its combination of strong early efficacy, clean safety results and solid funding, supporting the firm’s positive outlook on the stock.

-30-